KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Gross Margin (2016 - 2025)

Historic Gross Margin for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to 73.25%.

  • NovoCure's Gross Margin fell 39400.0% to 73.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 75.37%, marking a year-over-year decrease of 10400.0%. This contributed to the annual value of 77.33% for FY2024, which is 25200.0% up from last year.
  • As of Q3 2025, NovoCure's Gross Margin stood at 73.25%, which was down 39400.0% from 73.88% recorded in Q2 2025.
  • In the past 5 years, NovoCure's Gross Margin ranged from a high of 80.41% in Q1 2021 and a low of 73.01% during Q2 2023
  • In the last 5 years, NovoCure's Gross Margin had a median value of 77.19% in 2024 and averaged 76.79%.
  • As far as peak fluctuations go, NovoCure's Gross Margin soared by 44700bps in 2021, and later crashed by -67500bps in 2023.
  • NovoCure's Gross Margin (Quarter) stood at 77.71% in 2021, then decreased by 0bps to 77.51% in 2022, then dropped by -2bps to 75.67% in 2023, then increased by 5bps to 79.25% in 2024, then decreased by -8bps to 73.25% in 2025.
  • Its last three reported values are 73.25% in Q3 2025, 73.88% for Q2 2025, and 75.15% during Q1 2025.